Phreesia, Inc. PHR R2K
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. It offers solutions including appointment optimization and referral management using AI-enabled workflows; and AI-based smart answering solution patient communications supported by voice and messaging solutions; integrated payment solutions embedded in intake and post-visit workflows, and financing solutions that enable healthcare organizations to accelerate cash collections while offering flexible payment options to patients; and digital intake and clinical data capture, patient engagement and activation tools, and measurement and analytics solutions. It also offers PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, which are on-site kiosks. The company serves a range of healthcare organizations including ambulatory practices, health systems, and hospitals, as well as life sciences companies, government entities, patient advocacy, public interest and not-for-profit and other organizations. Phreesia, Inc. was incorporated in 2005 and is based in Wilmington, Delaware.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 19.6% over 5 years.
- Profit CAGR of 33.8% over 5 years.
- Generates positive free cash flow.
CONS
- Trading at a high P/E of 61.6.
- Trading 69.7% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PHR Phreesia, Inc. R2K | 9.86 | 61.62 | $609.09M | - | -0.41% | 2.86% | 19.60% | 33.77% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Apr 2018 | Jul 2018 | Oct 2018 | Jan 2019 | Apr 2019 | Jul 2019 | Oct 2019 | Jan 2020 | Apr 2020 | Jul 2020 | Oct 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Oct 2023 | Apr 2024 | Jul 2024 | Oct 2024 | Jan 2025 | Apr 2025 | Jul 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.87M | 24.78M | 24.76M | 26.48M | 28.31M | 30.82M | 32.84M | 32.81M | 33.40M | 35.01M | 38.46M | 48.29M | 51.01M | 55.91M | 63.35M | 67.87M | 73.10M | 83.84M | 85.83M | 91.62M | 101.22M | 102.11M | 106.80M | 109.68M | 115.94M | 117.25M | 120.33M | 127.07M | 130.94M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 33.57M | 38.06M | 37.64M | 38.03M | 40.39M | 43.33M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 76.11M | 77.87M | 79.61M | 82.31M | 86.68M | 87.60M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 83.73M | 81.16M | 81.12M | 78.57M | 92.23M | 80.85M |
| Operating Income | -1.91M | -1.25M | -3.04M | -3.30M | -4.25M | -4.14M | -2.23M | -4.67M | -4.97M | -6.31M | -6.11M | -10.65M | -23.81M | -35.74M | -50.59M | -46.34M | -39.81M | -37.90M | -36.95M | -32.05M | -19.42M | -17.22M | -13.84M | -7.61M | -3.29M | -1.51M | 3.74M | -5.56M | 6.75M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.03M | 4.13M | 7.24M | 12.92M | 5.17M | 16.98M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 586.00K | 435.00K | 391.00K | 320.00K | 5.81M | 2.30M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5.38M | -3.18M | -563.00K | 5.12M | -10.32M | 4.72M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01M | 735.00K | -1.22M | 854.00K | -11.62M | 1.76M |
| Net Income | -3.22M | -2.59M | -4.17M | -5.08M | -6.70M | -7.49M | -2.44M | -3.67M | -6.11M | -6.37M | -6.71M | -10.97M | -24.39M | -36.34M | -51.24M | -46.72M | -40.17M | -37.53M | -36.77M | -31.94M | -19.72M | -18.01M | -14.40M | -6.39M | -3.91M | 654.00K | 4.27M | 1.29M | 2.96M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | -0.17 | -0.17 | -0.24 | -0.48 | -0.71 | -0.99 | -0.89 | -0.76 | -0.70 | -0.68 | -0.58 | -0.35 | -0.31 | -0.25 | - | -0.07 | 0.01 | 0.07 | 0.02 | 0.05 |
| R&D Expense | - | - | 3.86M | - | 4.30M | 4.69M | 4.77M | - | 5.00M | 5.53M | 5.73M | 8.05M | 11.44M | 15.27M | 20.64M | 22.54M | 22.67M | 26.47M | 27.47M | 28.54M | 28.88M | 29.54M | 29.32M | - | 31.83M | 29.27M | 29.45M | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 280.91M | 356.30M | 419.81M | 480.59M |
| Cost of Revenue | - | - | - | - | - | 109.27M | 124.01M | 134.93M | 154.12M |
| Gross Profit | - | - | - | - | - | 171.64M | 232.29M | 284.88M | 326.47M |
| Operating Expenses | - | - | - | - | - | 348.19M | 368.77M | 342.98M | 333.08M |
| Operating Income | -14.55M | -9.49M | -15.30M | -25.67M | - | -176.55M | -136.48M | -58.10M | -6.61M |
| EBITDA | - | - | - | - | - | -148.95M | -104.00M | -25.58M | 29.47M |
| Interest Expense | - | - | - | - | - | 1.41M | 1.85M | 2.35M | 6.95M |
| Pretax Income | - | - | - | - | - | -175.66M | -135.34M | -55.81M | -8.94M |
| Tax Provision | - | - | - | - | - | 483.00K | 1.54M | 2.72M | -11.25M |
| Net Income | -18.19M | -15.06M | -20.29M | -27.29M | - | -176.15M | -136.88M | -58.53M | 2.31M |
| Diluted EPS | - | - | -4.50 | -0.69 | - | -3.36 | -2.51 | -1.02 | 0.04 |
| R&D Expense | 11.38M | 14.35M | 18.62M | 22.62M | 52.27M | 91.24M | 112.35M | 117.36M | 121.48M |
Compounded Sales Growth
| 5 Years: | 19.60% |
| 1 Year: | 12.90% |
Compounded Profit Growth
| 5 Years: | 33.77% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -59.74% |
| 6 Months: | -52.18% |
| 3 Months: | -20.03% |
| 1 Month: | +5.23% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jan 2017 | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 59.26M | 158.76M | 326.67M | - | 370.06M | 370.33M | 388.42M | 663.79M |
| Current Assets | - | - | - | - | - | - | 262.44M | 195.68M | 203.28M | 279.84M |
| Cash & Equivalents | - | - | 1.54M | 90.31M | 218.78M | - | 176.68M | 87.52M | 84.22M | 73.83M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | 51.46M | 62.88M | 70.34M | 93.30M |
| Total Liabilities | - | - | 63.75M | 56.89M | 63.36M | - | 82.24M | 118.88M | 123.61M | 326.58M |
| Current Liabilities | - | - | 27.93M | 35.35M | 54.99M | - | 79.04M | 110.12M | 114.02M | 183.24M |
| Long Term Debt | - | - | 27.92M | 19.44M | - | - | 2.73M | 2.05M | 719.00K | 90.00M |
| Total Debt | - | - | - | - | - | - | 9.18M | 11.98M | 17.80M | 102.45M |
| Total Equity | -130.46M | -167.68M | -210.97M | 101.86M | 263.31M | - | 287.82M | 251.45M | 264.81M | 337.21M |
| Shares Outstanding | - | - | - | - | - | - | 54.19M | 57.71M | 60.08M | 62.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -11.14M | -2.13M | 826.00K | 2.89M | - | -90.12M | -32.38M | 32.38M | 78.81M |
| Investing Cash Flow | -11.96M | -11.02M | -12.32M | -25.09M | - | -26.20M | -39.67M | -24.09M | -161.88M |
| Financing Cash Flow | 31.29M | 4.19M | 100.27M | 150.66M | - | -20.80M | -17.11M | -11.49M | 72.85M |
| Capital Expenditure | -6.59M | -4.72M | -7.01M | -11.24M | - | -26.20M | -25.10M | -24.09M | -24.40M |
| Free Cash Flow | -17.73M | -6.85M | -6.19M | -8.35M | - | -116.33M | -57.48M | 8.29M | 54.42M |
| Net Change in Cash | - | - | - | - | - | -137.13M | -89.16M | -3.19M | -10.21M |
Ratios (Annual)
Figures in %.
| Metric | Jan 2018 | Jan 2019 | Jan 2020 | Jan 2021 | Jan 2022 | Jan 2023 | Jan 2024 | Jan 2025 | Jan 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 61.1% | 65.2% | 67.9% | 67.9% |
| Operating Margin % | - | - | - | - | - | -62.9% | -38.3% | -13.8% | -1.4% |
| Net Margin % | - | - | - | - | - | -62.7% | -38.4% | -13.9% | 0.5% |
| ROE % | 10.8% | 7.1% | -19.9% | -10.4% | - | -61.2% | -54.4% | -22.1% | 0.7% |
| ROCE % | - | -30.3% | -12.4% | -9.4% | - | -60.7% | -52.5% | -21.2% | -1.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Pale Fire Capital SE | 14.00% | 8.65M | $85.28M |
| 2 | Blackrock Inc. | 9.58% | 5.92M | $58.38M |
| 3 | Vanguard Portfolio Management LLC | 5.40% | 3.34M | $32.88M |
| 4 | Vanguard Capital Management LLC | 4.01% | 2.48M | $24.45M |
| 5 | AQR Capital Management, LLC | 3.00% | 1.85M | $18.27M |
| 6 | State Street Corporation | 2.39% | 1.47M | $14.53M |
| 7 | Algert Global, LLC | 2.24% | 1.38M | $13.62M |
| 8 | Geode Capital Management, LLC | 2.22% | 1.37M | $13.53M |
| 9 | Prosight Management, Lp | 1.78% | 1.10M | $10.85M |
| 10 | Jacobs Levy Equity Management, Inc. | 1.74% | 1.08M | $10.61M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PHR